Andrea Wang-Gillam Selected Research

Pancreatic Neoplasms (Pancreatic Cancer)

1/2024	ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.
12/2023	A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
11/2023	Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.
10/2023	First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
1/2023	MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
12/2022	Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
11/2022	A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
1/2021	Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.
1/2021	Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation.
1/2021	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Wang-Gillam Research Topics

Disease

60	Neoplasms (Cancer) 01/2024 - 07/2008
48	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 01/2010
47	Adenocarcinoma 03/2024 - 08/2011
3	Exanthema (Rash) 01/2022 - 06/2013
3	Fatigue 01/2022 - 04/2015
3	Lymphopenia (Lymphocytopenia) 01/2022 - 04/2015
3	Rectal Neoplasms (Rectal Cancer) 01/2021 - 03/2014
3	Neutropenia 01/2021 - 01/2016
2	Thrombocytopenia (Thrombopenia) 12/2021 - 01/2019
2	Diarrhea 01/2021 - 01/2019
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 06/2019
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020 - 06/2017
2	Disease Progression 11/2016 - 12/2013
2	Febrile Neutropenia 01/2016 - 12/2014
2	Fever (Fevers) 04/2015 - 04/2004
2	Vitamin D Deficiency 09/2013 - 07/2008
1	Injection Site Reaction 10/2023
1	Melanoma (Melanoma, Malignant) 10/2023
1	Stomach Neoplasms (Stomach Cancer) 10/2023
1	Anemia 01/2023
1	Hemorrhage 01/2022
1	Leukopenia 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2021
1	Esophageal Squamous Cell Carcinoma 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	Ulcer 01/2021

Drug/Important Bio-Agent (IBA)

25	Gemcitabine FDA Link 12/2023 - 06/2013
15	Fluorouracil (Carac)FDA LinkGeneric 12/2023 - 03/2014
13	Irinotecan (Camptosar)FDA LinkGeneric 12/2023 - 02/2016
12	Leucovorin (Folinic Acid)FDA Link 12/2023 - 02/2016
9	130-nm albumin-bound paclitaxelIBA 01/2023 - 12/2013
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021 - 01/2013
6	folfirinoxIBA 01/2023 - 09/2012
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2023 - 06/2016
4	Proteins (Proteins, Gene)FDA Link 04/2017 - 06/2013
3	Biomarkers (Surrogate Marker)IBA 01/2024 - 02/2013
3	Vitamin D FDA LinkGeneric 12/2023 - 07/2008
3	pembrolizumabIBA 11/2023 - 01/2022
3	ulixertinibIBA 01/2023 - 01/2018
3	temsirolimus FDA Link 01/2021 - 08/2014
3	Docetaxel (Taxotere)FDA Link 01/2021 - 07/2015
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2020 - 04/2015
2	defactinibIBA 11/2023 - 12/2022
2	Interleukin-15 (Interleukin 15)IBA 10/2023 - 11/2021
2	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2022 - 01/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 06/2019
2	vorolanibIBA 01/2022 - 10/2021
2	MTOR InhibitorsIBA 10/2021 - 01/2021
2	Aurora Kinase AIBA 01/2021 - 02/2016
2	Capecitabine (Xeloda)FDA Link 02/2020 - 06/2019
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 04/2017
2	MesothelinIBA 09/2019 - 04/2015
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 04/2019 - 02/2017
2	AntigensIBA 03/2018 - 04/2015
2	VaccinesIBA 01/2018 - 04/2015
2	EnzymesIBA 04/2017 - 04/2015
2	AZD 6244IBA 04/2017 - 01/2013
2	taxaneIBA 07/2015 - 12/2014
1	Mitogen-Activated Protein KinasesIBA 03/2024
1	olaparibIBA 01/2024
1	Cell-Free Nucleic AcidsIBA 01/2024
1	HMPL-013IBA 12/2023
1	paricalcitol (Zemplar)FDA Link 12/2023
1	Interleukin-15 Receptors (Interleukin 15 Receptor)IBA 10/2023
1	spartalizumabIBA 10/2023
1	Monoclonal AntibodiesIBA 10/2023
1	ensituximabIBA 01/2023
1	racemetyrosineIBA 11/2022
1	Phenytoin (Dilantin)FDA LinkGeneric 11/2022
1	Sirolimus (Rapamycin)FDA Link 11/2022
1	Methoxsalen (Oxsoralen)FDA Link 11/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	cyclopropapyrroloindoleIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	NivolumabIBA 01/2022
1	LigandsIBA 12/2021
1	cobimetinibIBA 12/2021
1	atezolizumabIBA 12/2021
1	B7-H1 AntigenIBA 12/2021
1	Tyrosine Kinase InhibitorsIBA 10/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2021
1	Everolimus FDA Link 10/2021
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	MLN 8237IBA 01/2021
1	AntralIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021

Therapy/Procedure

27	Therapeutics 01/2024 - 07/2008
21	Drug Therapy (Chemotherapy) 01/2024 - 01/2012
7	Radiotherapy 01/2023 - 12/2013
4	Neoadjuvant Therapy 01/2024 - 01/2012
4	Immunotherapy 12/2022 - 09/2014
2	Pancreaticoduodenectomy 05/2015 - 08/2011
1	Drug Tapering 01/2021
1	Injections 01/2021
1	Intravenous Injections 01/2021